| Primary |
| Renal Transplant |
57.1% |
| Immunosuppressant Drug Therapy |
28.6% |
| Bone Marrow Transplant Rejection |
7.1% |
| Psoriatic Arthropathy |
7.1% |
|
| Hypertension |
16.7% |
| Kaposi's Sarcoma |
16.7% |
| Squamous Cell Carcinoma |
16.7% |
| Thrombocytopenia |
16.7% |
| Ventricular Tachycardia |
16.7% |
| Walking Disability |
16.7% |
|
| Secondary |
| Product Used For Unknown Indication |
11.9% |
| Colitis Ulcerative |
11.4% |
| Renal Transplant |
8.8% |
| Prophylaxis Against Transplant Rejection |
6.7% |
| Cryoglobulinaemia |
6.2% |
| Hepatitis C |
6.2% |
| Pyoderma Gangrenosum |
6.2% |
| Prophylaxis Against Graft Versus Host Disease |
5.7% |
| Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis |
5.2% |
| Hypersensitivity Vasculitis |
4.7% |
| Immunosuppression |
4.7% |
| Immunosuppressant Drug Therapy |
4.1% |
| Interstitial Lung Disease |
3.6% |
| Rheumatoid Arthritis |
3.6% |
| Urinary Tract Infection |
2.6% |
| Cytomegalovirus Infection |
2.1% |
| Hypertension |
1.6% |
| Juvenile Idiopathic Arthritis |
1.6% |
| Leukopenia |
1.6% |
| Lung Transplant |
1.6% |
|
| Off Label Use |
15.4% |
| Kaposi's Sarcoma |
7.7% |
| Polyneuropathy |
7.7% |
| Toxicity To Various Agents |
7.7% |
| Epstein-barr Virus Infection |
5.1% |
| Premature Baby |
5.1% |
| Rhabdomyolysis |
5.1% |
| Splenic Lesion |
5.1% |
| Squamous Cell Carcinoma |
5.1% |
| Transplant Rejection |
5.1% |
| Treatment Failure |
5.1% |
| Vomiting |
5.1% |
| Febrile Neutropenia |
2.6% |
| Foetal Growth Restriction |
2.6% |
| Gingival Pain |
2.6% |
| Hairy Cell Leukaemia |
2.6% |
| Immunosuppressant Drug Level Increased |
2.6% |
| Microsporum Infection |
2.6% |
| Mucosal Inflammation |
2.6% |
| Neoplasm Malignant |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
50.7% |
| Rheumatoid Arthritis |
6.5% |
| Bone Marrow Conditioning Regimen |
4.9% |
| Prophylaxis Against Graft Versus Host Disease |
3.9% |
| Psoriasis |
3.9% |
| Aplastic Anaemia |
3.7% |
| Prophylaxis |
3.0% |
| Hypertension |
2.4% |
| Hypophagia |
2.4% |
| Immunosuppression |
2.4% |
| Infection Prophylaxis |
2.2% |
| Hepatitis C |
2.1% |
| Chronic Lymphocytic Leukaemia |
1.9% |
| Diabetes Mellitus |
1.7% |
| Renal Transplant |
1.7% |
| Hordeolum |
1.5% |
| Polychondritis |
1.5% |
| Paroxysmal Nocturnal Haemoglobinuria |
1.4% |
| Pain |
1.2% |
| Drug Use For Unknown Indication |
1.1% |
|
| Renal Failure |
11.8% |
| T-cell Chronic Lymphocytic Leukaemia |
8.8% |
| Drug Ineffective |
7.4% |
| Pneumonia |
5.9% |
| Psoriasis |
5.9% |
| Sepsis |
5.9% |
| Stereotypy |
5.9% |
| Thrombocytopenia |
5.9% |
| Toxic Epidermal Necrolysis |
5.9% |
| Skin Atrophy |
4.4% |
| Therapeutic Response Unexpected |
4.4% |
| Vomiting |
4.4% |
| Convulsion |
2.9% |
| Cytomegalovirus Infection |
2.9% |
| Drug Ineffective For Unapproved Indication |
2.9% |
| Graft Versus Host Disease |
2.9% |
| Osteoporosis |
2.9% |
| Platelet Count Decreased |
2.9% |
| Polychondritis |
2.9% |
| Post Transplant Lymphoproliferative Disorder |
2.9% |
|
| Interacting |
| Bronchopulmonary Aspergillosis |
62.5% |
| Aplasia |
12.5% |
| Product Used For Unknown Indication |
12.5% |
| Prophylaxis |
12.5% |
|
| Respiratory Distress |
100.0% |
|
